Discover a new way to find and share stories you'll loveā€¦ Learn about Reading Desk

Post Profile



A.P. Pharma: Refiling Of NDA For APF530 Could Cause Price Strength

By Smith On Stocks: Catalyst AP Pharma (APPA.OB) announced that it has resubmitted its New Drug Application (NDA) to the FDA for its lead product candidate, APF530, for the prevention of acute and delayed onset chemotherapy-induced nausea and vomiting (CINV). A.P. Pharma expects to be notified that the FDA has accepted the refiling and has established a Prescription Drug User Fee Act (PDUFA) goal date within the next 60 days or so.
read more

share

Copyright © 2011 Regator, LLC